Rheumatoid arthritis (RA) is an inflammatory disease of the joints characterized by pain, stiffness, and swelling, as well as an eventual loss of limb function. Rheumatoid arthritis affects about one percent of the population, primarily women.
The use of cannabis to treat symptoms of RA is frequently self-reported by patients. In a 2005 anonymous questionnaire survey of medicinal cannabis patients in Australia, 25 percent reported using cannabinoids to treat RA. A survey of British medical cannabis patients found that more than 20 percent of respondents reported using cannabis for symptoms of arthritis. A review of state-registered medical cannabis pain patients reported that 27 percent used it to treat arthritis. Nevertheless, there exists limited clinical data with respect to the use of cannabinoids on RA in the literature at this time.
In January 2006, investigators at the British Royal National Hospital for Rheumatic Disease reported successful treatment of arthritis with cannabinoids in the first-ever controlled trial assessing the efficacy of natural cannabis extracts on RA. Investigators reported that the administration of cannabis extracts over a five week period produced statistically significant improvements in pain on movement, pain at rest, quality of sleep, inflammation and intensity of pain compared to placebo. No serious adverse effects were observed. Similar results had been reported in smaller trials investigating the use of orally administered cannabis extracts on symptoms of RA. A randomized, placebo-controlled trial assessing the use of vaporized cannabis in osteoarthritis patients began in Canada in 2016. Nonetheless, the limited number of studies and their short-term duration "allows for only limited conclusions for the effects of cannabinoids in rheumatic conditions."
Preclinical data indicates that cannabinoids moderate RA progression. Writing in the Journal of the Proceedings of the National Academy of Sciences, investigators at London's Kennedy Institute for Rheumatology reported that cannabidiol administration suppressed the progression of arthritis in vitro and in animals. Administration of CBD after the onset of clinical symptoms protected joints against severe damage and "effectively blocked [the] progression of arthritis," investigators concluded. Daily administration of the synthetic cannabinoid agonist HU-320 has also been reported to protect joints from damage and to ameliorate arthritis in preclinical models, as has the administration of the cannabinoid agonist HU-444.
Summarizing the available literature in the Journal of Neuroimmunology, researchers at Tokyo's National Institute for Neuroscience concluded, "Cannabinoid therapy of RA could provide symptomatic relief of joint pain and swelling as well as suppressing joint destruction and disease progression." More recently, experts in the field have opined that "specific activation of CB2 (receptor) may relieve RA" and that "a selective CB(2) agonist could be a new therapy for RA."
 Zaka et al. 2017. Comparative in silico analyses of Cannabis sativa, Prunella vulgaris and Withania somnifera compounds elucidating the medicinal properties against rheumatoid arthritis. Journal of Molecular Graphs & Modeling 74: 296-304.
 Swift et al. 2005. Survey of Australians using cannabis for medical purposes. Harm Reduction Journal 4: 2-18.
 Ware et al. 2005. The medicinal use of cannabis in the UK: results of a nationwide survey. International Journal of Clinical Practice 59: 291-295.
 Aggarwal et al. 2009. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington state. Journal of Opioid Management 5: 257-286.
 Blake et al. 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45: 50-52.
 PR Newswire. "First Health Canada approved medical cannabis clinical trial starts patient recruitment," June 23, 2015.
 Fitzcharles et al. 2016. Efficacy, tolerability, and safety of cannabinoid treatments in the rheutmatic diseases: A systematic review of randomized controlled trials. Arthritis Care and Research 68: 681-688.
 Malfait et al. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine. Journal of the Proceedings of the National Academy of Sciences 97: 9561-9566.
 Sumariwalla et al. 2004. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with anti-inflammatory properties in murine collagen-induced arthritis. Arthritis & Rheumatism 50: 985-998.
 Haj et al. 2015. HU-444, a novel, potent anti-inflammatory, non-psychotropic cannabinoid. The Journal of Pharmacology and Experimental Therapeutics. 355: 66-75.
 Croxford and Yamamura. 2005. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases. Journal of Neuroimmunology 166: 3-18.
 Gui et al. Op. cit.
 Fukuda et al. 2014. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskeletal Disorders 15: 275.